A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Sponsor: Oscotec Inc.



Oscotec Inc 
Protocol: OSCO-P220 I Version 5.0 Amendment 4 
Protocol Approval - Sponsor Signatory 
SKl-O-703 
19 Oct 2020 
Study Title 
A Phase 2, Multicenter, Randomized, Double-Blind, 
Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and 
Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis 
Despite Treatment With Conventional Therapies 
Protocol Number 
OSCO-P2201 
Protocol Date 
19 Oct 2020 
Protocol accepted and approved by: 
Page 3268

Oscotec Inc 
Protocol: OSCO-P2201 Version 5.0 Amendment 4 
Protocol Approval - Principal/Coordinating Investigator 
SKl-O-703 
19 Oct 2020 
Study Title 
A Phase 2, Multicenter, Randomized, Double-Blind, 
Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and 
Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis 
Despite Treatment With Conventional Therapies 
Protocol N um her
OSCO-P2201 
Protocol Date 
19 Oct 2020 
Protocol accepted and approved by: 
Page 3269